OptimizeRx Corporation
OPRX
$14.62
$0.443.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.37% | 13.91% | 30.48% | 36.14% | 51.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.37% | 13.91% | 30.48% | 36.14% | 51.43% |
| Cost of Revenue | 14.67% | -2.23% | 20.38% | 18.61% | 34.40% |
| Gross Profit | 9.34% | 23.44% | 37.21% | 49.57% | 64.19% |
| SG&A Expenses | -11.15% | 18.57% | 4.18% | 17.78% | 15.21% |
| Depreciation & Amortization | 2.53% | 8.64% | 134.48% | 130.75% | 129.96% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.74% | 9.80% | 12.56% | 20.86% | 23.19% |
| Operating Income | 57.96% | 61.65% | 69.80% | 22.69% | 28.80% |
| Income Before Tax | 49.90% | 118.81% | -246.98% | -23.45% | -2.45% |
| Income Tax Expenses | -415.41% | 130.09% | -- | -3,396.97% | -- |
| Earnings from Continuing Operations | 68.13% | 98.12% | -218.46% | 3.68% | -7.83% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.13% | 98.12% | -218.46% | 3.68% | -7.83% |
| EBIT | 57.96% | 61.65% | 69.80% | 22.69% | 28.80% |
| EBITDA | 71.28% | 48.48% | 95.81% | 36.97% | 38.79% |
| EPS Basic | 68.63% | 98.20% | -189.14% | 10.37% | -1.44% |
| Normalized Basic EPS | 50.73% | 51.01% | 22.30% | -14.89% | 3.59% |
| EPS Diluted | 68.42% | 98.26% | -190.36% | 10.17% | -1.52% |
| Normalized Diluted EPS | 50.73% | 51.01% | 22.30% | -14.89% | 3.59% |
| Average Basic Shares Outstanding | 1.65% | 3.61% | 10.13% | 7.45% | 6.29% |
| Average Diluted Shares Outstanding | 1.65% | 3.61% | 10.13% | 7.45% | 6.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |